Cohance Lifesciences Expands Bioconjugation and Manufacturing Capacities

Cohance Lifesciences has announced a $10 million investment to enhance bioconjugation capabilities at its NJ Bio subsidiary in the U.S., alongside a Rs 23 crore investment in Hyderabad. These expansions aim to support global innovators in antibody-drug conjugate development and oligonucleotide building block manufacturing.

Cohance Lifesciences revealed a strategic $10 million investment to bolster its bioconjugation capabilities at NJ Bio, its U.S.-based subsidiary. This move aims to fortify the company's global expansion in innovative technologies, supporting clients from initial development through to late-phase clinical supply.

Located in Princeton, New Jersey, NJ Bio's cutting-edge facility now offers enhanced common good manufacturing practices (cGMP) compliant bioconjugation suites. This development empowers Cohance to deliver comprehensive Antibody-Drug Conjugate (ADC) solutions, integrating payload-linker development with bioconjugation processes.

Further reinforcing its position, Cohance also announced an Rs 23 crore investment in Hyderabad's new oligonucleotide building block manufacturing facility, demonstrating significant strides in its capacity expansion program, which targets serving global innovators across high-growth modalities.

(With inputs from agencies.)